The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

In all, researchers found that people taking GLP-1 medications had lower risks for 42 health outcomes, including liver ...

Novo Nordisk ( NYSE:NVO) and Eli Lilly ( NYSE:LLY) are making headlines againthis time, for potential benefits beyond weight ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...

An observational study of 175 health outcomes using Veterans Affairs (VA) data for nearly 2 million individuals uncovered new ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...

GLP-1 class of weight loss and diabetes drugs are linked to previously unrecognized health risks and benefits, according to a ...

Health-care companies rose after more promising data for the best-selling Glucagon-like Peptide inhibitor drugs. Shares of Novo Nordisk and Eli Lilly, the two leading producers of GLP-1 drugs, rallied ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduc ...

Discover the unexpected health benefits of diabetes and weight loss medications like Ozempic and Wegovy. Find out how these ...